Abstract
Previous work by Judah Folkman had indicated that abnormal vascularization could be inhibited and that this could have a beneficial effect in pathological situations where vascularization was excessive. Many pharmacological substances are indeed capable of inhibiting the growth of endothelial cells, including synthetic molecules, plant extracts, and snake venoms.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Folkman J (2006) Angiogenesis. Annu Rev Med 57:1–18. https://doi.org/10.1146/annurev.med.57.121304.131306
O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J (1997) Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88(2):277–285
Boehm T, Folkman J, Browder T, O’Reilly MS (1997) Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390(6658):404–407. https://doi.org/10.1038/37126
Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin CH (1994) Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. J Biol Chem 269(43):26988–26995
Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A (1996) Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature 380(6573):435–439. https://doi.org/10.1038/380435a0
Kolata G (1998) Two drugs eradicate tumors in mice. New York Times, May 3
Xie L, Duncan MB, Pahler J, Sugimoto H, Martino M, Lively J, Mundel T, Soubasakos M, Rubin K, Takeda T, Inoue M, Lawler J, Hynes RO, Hanahan D, Kalluri R (2011) Counterbalancing angiogenic regulatory factors control the rate of cancer progression and survival in a stage-specific manner. Proc Natl Acad Sci U S A 108(24):9939–9944. https://doi.org/10.1073/pnas.1105041108
Murphy-Ullrich JE, Sage EH (2014) Revisiting the matricellular concept. J Int Soc Matrix Biol 37:1–14. https://doi.org/10.1016/j.matbio.2014.07.005
Ferrara N, Hillan KJ, Novotny W (2005) Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333(2):328–335. https://doi.org/10.1016/j.bbrc.2005.05.132
Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350(23):2335–2342. https://doi.org/10.1056/NEJMoa032691
Yancopoulos GD (2010) Clinical application of therapies targeting VEGF. Cell 143(1):13–16. https://doi.org/10.1016/j.cell.2010.09.028
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Bikfalvi, A. (2017). Inhibition of Angiogenesis, “Disappointments and Success”. In: A Brief History of Blood and Lymphatic Vessels. Springer, Cham. https://doi.org/10.1007/978-3-319-74376-9_8
Download citation
DOI: https://doi.org/10.1007/978-3-319-74376-9_8
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-74375-2
Online ISBN: 978-3-319-74376-9
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)